In December 2005, Eli Lilly and Business agreed to plead guilty and spend $36 million in reference to the unlawful marketing with the drug.[264] Profits Reps were qualified to market Evista for breast most cancers and cardiovascular disease, to prompt or bait issues by Health professionals, and